<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    18279051
   </pmid>
   <datecreated>
    <year>
     2008
    </year>
    <month>
     04
    </month>
    <day>
     18
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2008
    </year>
    <month>
     06
    </month>
    <day>
     05
    </day>
   </datecompleted>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0022-1899
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       197
      </volume>
      <issue>
       6
      </issue>
      <pubdate>
       <year>
        2008
       </year>
       <month>
        Mar
       </month>
       <day>
        15
       </day>
      </pubdate>
     </journalissue>
     <title>
      The Journal of infectious diseases
     </title>
     <isoabbreviation>
      J. Infect. Dis.
     </isoabbreviation>
    </journal>
    <articletitle>
     Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate.
    </articletitle>
    <pagination>
     <medlinepgn>
      795-802
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Zinc lozenges have been used for treatment of the common cold; however, the results remain controversial.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Fifty ambulatory volunteers were recruited within 24 h of developing symptoms of the common cold for a randomized, double-blind, placebo-controlled trial of zinc. Participants took 1 lozenge containing 13.3 mg of zinc (as zinc acetate) or placebo every 2-3 h while awake. The subjective scores for common cold symptoms were recorded daily. Plasma zinc, soluble interleukin (IL)-1 receptor antagonist (sIL-1ra), soluble tumor necrosis factor receptor 1, soluble vascular endothelial cell adhesion molecule, and soluble intercellular adhesion molecule (sICAM)-1 were assayed on days 1 and 5.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Compared with the placebo group, the zinc group had a shorter mean overall duration of cold (4.0 vs. 7.1 days; P &lt; .0001) and shorter durations of cough (2.1 vs. 5.0 days; P &lt; .0001) and nasal discharge (3.0 vs. 4.5 days, P = .02) Blinding of subjects was adequate, and adverse effects were comparable in the 2 groups. Symptom severity scores were decreased significantly in the zinc group. Mean changes in plasma levels of zinc, sIL-1ra, and ICAM-1 differed significantly between groups.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Administration of zinc lozenges was associated with reduced duration and severity of cold symptoms. We related the improvement in cold symptoms to the antioxidant and anti-inflammatory properties of zinc.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA. prasada@karmanos.org
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Prasad
      </lastname>
      <forename>
       Ananda S
      </forename>
      <initials>
       AS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Beck
      </lastname>
      <forename>
       Frances W J
      </forename>
      <initials>
       FW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bao
      </lastname>
      <forename>
       Bin
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Snell
      </lastname>
      <forename>
       Diane
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fitzgerald
      </lastname>
      <forename>
       James T
      </forename>
      <initials>
       JT
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <grantlist completeyn="Y">
     <grant>
      <grantid>
       5 R01 A150698-04
      </grantid>
      <agency>
       PHS HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
    </grantlist>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, N.I.H., Extramural
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     J Infect Dis
    </medlineta>
    <nlmuniqueid>
     0413675
    </nlmuniqueid>
    <issnlinking>
     0022-1899
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Interleukin 1 Receptor Antagonist Protein
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Receptors, Tumor Necrosis Factor
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      126547-89-5
     </registrynumber>
     <nameofsubstance>
      Intercellular Adhesion Molecule-1
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      5970-45-6
     </registrynumber>
     <nameofsubstance>
      Zinc Acetate
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Common Cold
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Intercellular Adhesion Molecule-1
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Interleukin 1 Receptor Antagonist Protein
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Receptors, Tumor Necrosis Factor
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Severity of Illness Index
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Zinc Acetate
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2008
     </year>
     <month>
      2
     </month>
     <day>
      19
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2008
     </year>
     <month>
      6
     </month>
     <day>
      6
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2008
     </year>
     <month>
      2
     </month>
     <day>
      19
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="doi">
     10.1086/528803
    </articleid>
    <articleid idtype="pubmed">
     18279051
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

